1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, min. 98% DOTA|07-1942|60239-18-1

1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, min. 98% DOTA

$1,260.00

FREE
SHIPPING

100% MONEY
BACK GUARANTEE

ONLINE
SUPPORT 24/7

Available on backorder. Please allow 4-6 weeks for production.
Sku SC07-1942_5_G
US-Strem
Get Bulk Quote

Product Information

Product Name
1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, min. 98% DOTA
Brand Name
US-Strem
Product Number
07-1942
CAS
60239-18-1
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
121841
IUPAC Name
2-4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-ylacetic acid
InChI Key
WDLRUFUQRNWCPK-UHFFFAOYSA-N
SMILES
C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O

References Data Source From Pubchem

First αvβ6-integrin targeted radioligand therapy of breast cancer using Lu-177-Therahexin
Publication Name: European Journal of Nuclear Medicine and Molecular Imaging
Publication Date: 2026-02-26
DOI: 10.1007/s00259-026-07826-1

Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective
Publication Name: AAPS PharmSciTech
Publication Date: 2026-02-26
DOI: 10.1208/s12249-026-03346-1

Exploring the theranostic potential of two metabolically stable GRPR-targeting peptides labelled with Ga-68 for PET imaging
Publication Name: EJNMMI Radiopharmacy and Chemistry
Publication Date: 2026-02-17
DOI: 10.1186/s41181-026-00431-5

[177Lu]Lu-PSMA radioligand therapy in systemic therapy-naïve metastatic hormone-sensitive prostate cancer patients: a retrospective study
Publication Name: European Journal of Nuclear Medicine and Molecular Imaging
Publication Date: 2026-02-13
DOI: 10.1007/s00259-026-07802-9

Approvals by the China NMPA in 2025
Publication Name: Nature reviews. Drug discovery
Publication Date: 2026-02-13
DOI: 10.1038/d41573-026-00028-2